AIMD
Ainos, Inc.
There isn't enough reported data to score AIMD yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AIMD Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
AIMD's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AIMD PE Valuation
AIMD has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AIMD Forward outlook
There aren't enough analyst estimates for AIMD to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AIMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$3.29 | +$1.25 |
| Q1 2026 | -$3.66 | +$2.34 |
| Q4 2025 | -$4.30 | +$3.50 |
| Q2 2021 | -$11.25 | +$7.50 |
| Q1 2021 | -$15.00 | $0.00 |
| Q4 2020 | -$15.00 | $0.00 |
| Q3 2020 | -$18.75 | -$3.75 |
AIMD has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
AIMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $152 | -97% |
| Q1 2026 | $161 | -100% |
| Q1 2025 | $106.2K | +412% |
| Q1 2024 | $20.7K | -58% |
| Q4 2023 | $19.9K | -98% |
| Q3 2023 | $24.5K | -99% |
| Q2 2023 | $28.6K | -96% |
| Q1 2023 | $49.2K | -44% |
AIMD's revenue has slid since its 2022 peak: $152 last quarter, down 97% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2894136% | -2813808 points |
| Q1 2026 | -1418414% | -1415436 points |
| Q4 2025 | -38648% | N/A |
| Q3 2025 | -128481% | N/A |
| Q2 2025 | -80328% | N/A |
| Q1 2025 | -2978% | +12074 points |
| Q1 2024 | -15052% | -9940 points |
| Q4 2023 | -28643% | -28438 points |
AIMD's operating margin was −2894136% last quarter, down 2813808 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over AIMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over AIMD on profitability, with a higher operating margin.
AIMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.5M | -$111.4K |
| Q1 2026 | -$992K | +$266.3K |
| Q4 2025 | -$853.5K | +$11.7K |
| Q3 2025 | -$1.2M | +$290.5K |
| Q2 2025 | -$1.3M | +$637.3K |
| Q1 2025 | -$1.3M | +$241K |
| Q4 2024 | -$865.1K | +$492.9K |
| Q2 2024 | -$2M | -$829K |
AIMD has burned cash in almost every quarter: −$4M over the past year, against −$5M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over AIMD on cash generation, producing positive trailing cash flow while its opponent burns cash.
AIMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +22% | +1.3M shares |
| 1 year | +132% | +4.2M shares |
| 3 years | +819% | +6.6M shares |
| 5 years | +6709% | +7.2M shares |
AIMD has 7M diluted shares, up 132% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over AIMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
AIMD Net Leverage
AIMD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AIMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.6 | Neutral |
| Stochastic | 19.5 | Oversold |
AIMD's weekly RSI is 43 (neutral) and its Stochastic is 20 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AIMD PE vs Healthcare Sector
AIMD has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
AIMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.01 | 5% above |
| 20 week MA | $1.32 | 20% below |
| 50 week MA | $1.60 | 34% below |
| 100 week MA | $2.30 | 54% below |
| 200 week MA | $6.77 | 84% below |
AIMD has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AIMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $57.4 | $255.0 | +344% |
| 2022 | $255.0 | $15.7 | -94% |
| 2023 | $15.7 | $10.3 | -35% |
| 2024 | $10.3 | $2.27 | -78% |
| 2025 | $2.27 | $1.95 | -14% |
| 2026 YTD | $1.95 | $1.06 | -46% |
AIMD has finished four years in a row lower, and it's down 46% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over AIMD on returns for 2026, with the stronger performance.